In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Akebia Therapeutics Inc. (NASDAQ: AKBA) was $1.42 for the day, up 8.40% from the previous closing price of $1.31. In other words, the price has increased by $8.40 from its previous closing price. On the day, 3.78 million shares were traded. AKBA stock price reached its highest trading level at $1.46 during the session, while it also had its lowest trading level at $1.3147.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.70.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 13 ’24 when Dahan Michel sold 34,840 shares for $1.26 per share. The transaction valued at 43,898 led to the insider holds 672,092 shares of the business.
Hadas Nicole R. sold 12,016 shares of AKBA for $15,140 on May 13 ’24. The SVP, Chief Legal Officer now owns 651,243 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Butler John P., who serves as the CEO and President of the company, sold 46,570 shares for $1.58 each. As a result, the insider received 73,581 and left with 2,044,580 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 297626304 and an Enterprise Value of 354009856. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59. Its current Enterprise Value per Revenue stands at 1.891 whereas that against EBITDA is 89.261.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.80, which has changed by 0.14516127 over the last 52 weeks, in comparison to a change of 0.24125004 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.78. The 50-Day Moving Average of the stock is 27.48%, while the 200-Day Moving Average is calculated to be 11.93%.
Shares Statistics:
AKBA traded an average of 3.28M shares per day over the past three months and 3052460 shares per day over the past ten days. A total of 194.58M shares are outstanding, with a floating share count of 191.52M. Insiders hold about 8.62% of the company’s shares, while institutions hold 20.91% stake in the company. Shares short for AKBA as of 1719532800 were 13114139 with a Short Ratio of 4.00, compared to 1717113600 on 13155199. Therefore, it implies a Short% of Shares Outstanding of 13114139 and a Short% of Float of 6.3200004000000005.
